-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
This article is reproduced from the WeChat public account Axon Neuroscience of "DrugMaker" today announced that the complete results of the Phase 2 clinical trial of its tau protein vaccine AADvac1 for the treatment of Alzheimer's disease (AD) were published in the sub-Journal Nature Aging
.
The test results show that AADvac1 has excellent safety and stimulates a strong antibody response, which has a significant impact on neurodegeneration
.
In a 24-month randomized double-blind, placebo-controlled phase 2 clinical trial, AADvac1 reached the primary endpoint of the trial, showing good safety and tolerability
.
In addition, AADvac1 significantly reduced the accumulation of nerve fiber light chain (NfL)
.
NfL is an important biomarker of neurodegeneration, and AADvac1 reduces the level of NfL in the blood by 58% (P=0.
004)
.
In the subgroup of AD patients confirmed by AD biomarkers amyloid deposition and tau protein aggregation, AADvac1, compared with placebo, delayed the clinical decline detected by CDR-SB by 27% (p=0.
048), and will pass The functional deterioration of ADCS-MCI-ADL detection was delayed by 30% (p=0.
039)
.
In this subgroup of patients, the level of NfL in the blood was reduced by 62% compared with the placebo group (p=0.
010)
.
End's selection of onlookers ophthalmology top issue in the past is a big hit! If you drink too much coffee or cause blindness, beware of the "cancer" in eye diseases stealing your vision.
The FDA approved Biogen's new drug for Alzheimer's disease caused public outrage.
3 members of the expert team resigned! Rewen's new research reveals: staying up late will really "become stupid"! During sleep, the brain will start the "detox" program to clear out the junk and hot text in the brain.
How about the children who have been infected with the new crown? Chinese scientists reveal the relationship between the new coronavirus and the microbial flora in children.
New discoveries in cancer treatment! Nature reveals the "dormancy" mechanism of tumor cells to effectively prevent metastatic cancer.
Medical immunotherapy | Biosimilars | Vaccines | Drug resistance | Drug targets | Healthy life | Pharmaceutical company news | Drug inventory | Pharmaceutical technology | Basic research/transformation of drug side effects Medical Leukemia| Lung Cancer| Stomach Cancer| Colorectal Cancer| Liver Cancer| Breast Cancer| Pancreatic Cancer| Cardiovascular Disease| Neurodegenerative Disease| Intestinal Microbial Medical Devices/Biotechnology In Vitro Diagnosis| Medical Devices| Bio-Nano| 3D Printing| Genetic Testing | Single Cell Sequencing | Gene Editing | Assisted Reproduction | Artificial Intelligence | Precision Medicine Policy Anti-cancer Drugs | 4+7 Quantity Procurement | Consumables | Record-keeping System | Registrant System | Healthy China | New Essential Medicine Catalog | AI Medical Devices | Remote Medical | Same stock market with different rights/capital IPO | Financing | Cooperation | Funds | Hong Kong Stock Exchange | Science and Technology Innovation Board | ChiNext Board | R & D Investment | Acquisitions | Market & Consumption
.
The test results show that AADvac1 has excellent safety and stimulates a strong antibody response, which has a significant impact on neurodegeneration
.
In a 24-month randomized double-blind, placebo-controlled phase 2 clinical trial, AADvac1 reached the primary endpoint of the trial, showing good safety and tolerability
.
In addition, AADvac1 significantly reduced the accumulation of nerve fiber light chain (NfL)
.
NfL is an important biomarker of neurodegeneration, and AADvac1 reduces the level of NfL in the blood by 58% (P=0.
004)
.
In the subgroup of AD patients confirmed by AD biomarkers amyloid deposition and tau protein aggregation, AADvac1, compared with placebo, delayed the clinical decline detected by CDR-SB by 27% (p=0.
048), and will pass The functional deterioration of ADCS-MCI-ADL detection was delayed by 30% (p=0.
039)
.
In this subgroup of patients, the level of NfL in the blood was reduced by 62% compared with the placebo group (p=0.
010)
.
End's selection of onlookers ophthalmology top issue in the past is a big hit! If you drink too much coffee or cause blindness, beware of the "cancer" in eye diseases stealing your vision.
The FDA approved Biogen's new drug for Alzheimer's disease caused public outrage.
3 members of the expert team resigned! Rewen's new research reveals: staying up late will really "become stupid"! During sleep, the brain will start the "detox" program to clear out the junk and hot text in the brain.
How about the children who have been infected with the new crown? Chinese scientists reveal the relationship between the new coronavirus and the microbial flora in children.
New discoveries in cancer treatment! Nature reveals the "dormancy" mechanism of tumor cells to effectively prevent metastatic cancer.
Medical immunotherapy | Biosimilars | Vaccines | Drug resistance | Drug targets | Healthy life | Pharmaceutical company news | Drug inventory | Pharmaceutical technology | Basic research/transformation of drug side effects Medical Leukemia| Lung Cancer| Stomach Cancer| Colorectal Cancer| Liver Cancer| Breast Cancer| Pancreatic Cancer| Cardiovascular Disease| Neurodegenerative Disease| Intestinal Microbial Medical Devices/Biotechnology In Vitro Diagnosis| Medical Devices| Bio-Nano| 3D Printing| Genetic Testing | Single Cell Sequencing | Gene Editing | Assisted Reproduction | Artificial Intelligence | Precision Medicine Policy Anti-cancer Drugs | 4+7 Quantity Procurement | Consumables | Record-keeping System | Registrant System | Healthy China | New Essential Medicine Catalog | AI Medical Devices | Remote Medical | Same stock market with different rights/capital IPO | Financing | Cooperation | Funds | Hong Kong Stock Exchange | Science and Technology Innovation Board | ChiNext Board | R & D Investment | Acquisitions | Market & Consumption
